A two-part, phase I/Ib, open-label, dose-escalation trial of tumor necrosis factor alpha and interleukin-2 coding oncolytic adenovirus (TILT-123) in combination with pembrolizumab (phase i part) and pembrolizumab and pegylated liposomal doxorubicin (phase ib part) in patients with platinum-resistant or refractory ovarian cancer. Here, TNF is linked to ovarian carcinoma.